We did not detect differences in the response to IFN-β between LCLs from MS and healthy controls for NEXN, DDX60L and IGFBP4, but for HAPLN3 a slight increase in expression was found in control samples (P = 0.048) (Fig. 4A). This evidence concerns the gene NEXN and myeloid sarcoma.